Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects Following Dose-Escalating Single Intravenous or Subcutaneous Administration

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects Following Dose-Escalating Single Intravenous or Subcutaneous Administration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DISC 0974 (Primary) ; DISC 0974 (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Disc Medicine

Most Recent Events

  • 13 Dec 2022 Results assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DISC-0974 in healthy volunteers, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Results published in the Disc Medicine Media Release.
  • 13 Dec 2022 According to a Disc Medicine media release, data from the study were presented at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top